Compare Piramal Healthcare with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs NOVARTIS - Comparison Results

PIRAMAL ENTERPRISES     Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES NOVARTIS PIRAMAL ENTERPRISES/
NOVARTIS
 
P/E (TTM) x -31.8 2,092.6 - View Chart
P/BV x 1.1 27.8 3.9% View Chart
Dividend Yield % 2.1 1.6 133.4%  

Financials

 PIRAMAL ENTERPRISES   NOVARTIS
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-19
NOVARTIS
Mar-19
PIRAMAL ENTERPRISES/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs3,303980 337.0%   
Low Rs1,797600 299.4%   
Sales per share (Unadj.) Rs716.5198.7 360.5%  
Earnings per share (Unadj.) Rs79.721.0 380.1%  
Cash flow per share (Unadj.) Rs107.922.3 484.8%  
Dividends per share (Unadj.) Rs28.0010.00 280.0%  
Dividend yield (eoy) %1.11.3 86.8%  
Book value per share (Unadj.) Rs1,477.5307.5 480.5%  
Shares outstanding (eoy) m184.4524.69 747.1%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x3.64.0 89.5%   
Avg P/E ratio x32.037.7 84.9%  
P/CF ratio (eoy) x23.635.5 66.6%  
Price / Book Value ratio x1.72.6 67.2%  
Dividend payout %35.147.7 73.7%   
Avg Mkt Cap Rs m470,29219,508 2,410.8%   
No. of employees `0007.80.6 1,346.0%   
Total wages/salary Rs m22,5041,171 1,921.6%   
Avg. sales/employee Rs Th16,899.48,445.4 200.1%   
Avg. wages/employee Rs Th2,877.72,015.7 142.8%   
Avg. net profit/employee Rs Th1,879.9891.0 211.0%   
INCOME DATA
Net Sales Rs m132,1534,907 2,693.3%  
Other income Rs m3,128783 399.7%   
Total revenues Rs m135,2815,689 2,377.8%   
Gross profit Rs m66,290123 53,981.8%  
Depreciation Rs m5,20232 16,356.9%   
Interest Rs m44,09716 277,342.1%   
Profit before tax Rs m20,119858 2,345.7%   
Minority Interest Rs m3,1940-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,611340 2,532.7%   
Profit after tax Rs m14,701518 2,839.7%  
Gross profit margin %50.22.5 2,004.3%  
Effective tax rate %42.839.6 108.0%   
Net profit margin %11.110.6 105.4%  
BALANCE SHEET DATA
Current assets Rs m122,7428,055 1,523.9%   
Current liabilities Rs m310,8101,850 16,799.6%   
Net working cap to sales %-142.3126.4 -112.5%  
Current ratio x0.44.4 9.1%  
Inventory Days Days2345 51.2%  
Debtors Days Days3934 114.5%  
Net fixed assets Rs m116,904150 78,040.2%   
Share capital Rs m369123 298.9%   
"Free" reserves Rs m272,1617,469 3,644.1%   
Net worth Rs m272,5307,592 3,589.8%   
Long term debt Rs m270,1960-   
Total assets Rs m856,2619,824 8,715.7%  
Interest coverage x1.554.9 2.7%   
Debt to equity ratio x1.00-  
Sales to assets ratio x0.20.5 30.9%   
Return on assets %6.95.4 126.4%  
Return on equity %5.46.8 79.1%  
Return on capital %12.411.5 107.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,20058 26,389.6%   
Fx outflow Rs m4,8891,326 368.6%   
Net fx Rs m10,312-1,269 -812.8%   
CASH FLOW
From Operations Rs m-115,975-1,943 5,969.5%  
From Investments Rs m-8,2652,742 -301.4%  
From Financial Activity Rs m107,525-298 -36,057.9%  
Net Cashflow Rs m-16,650501 -3,321.4%  

Share Holding

Indian Promoters % 52.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 4.0 2.0 200.0%  
FIIs % 26.6 1.6 1,662.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 21.5 76.7%  
Shareholders   93,274 41,647 224.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   SUN PHARMA  ORCHID PHARMA  GSK PHARMA  FULFORD INDIA  PROCTER & GAMBLE HEALTH  

Compare PIRAMAL ENTERPRISES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Snap 4-Day Winning Streak; Smallcap Stocks Outperform(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended marginally lower.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY21); Net Profit Up 22.1% (Quarterly Result Update)

Aug 25, 2020 | Updated on Aug 25, 2020

For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY20); Net Profit Up 11.7% (Quarterly Result Update)

Feb 5, 2020 | Updated on Feb 5, 2020

For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY20); Net Profit Up 16.5% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 16.5% YoY). Sales on the other hand came in at Rs 36 bn (up 14.6% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

My Latest Stock Recommendation(Fast Profits Daily)

Oct 9, 2020

How I picked an exciting stock using trends from both the commodity and equity markets.

The 'Seedhi Baat, No Bakwaas' View on ITC(Profit Hunter)

Oct 12, 2020

Is ITC an investment or a speculation at current levels?

One of the Best Investment Opportunities in the Market Right Now(Fast Profits Daily)

Oct 16, 2020

The one sector that you should be looking at to make good profits.

The Inflection Point for Defence Stocks is Getting Closer(Profit Hunter)

Oct 9, 2020

Few Indian defence companies could use their engineering capabilities to eventually become global leaders.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Oct 22, 2020 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS